PD-L1 CPS utilizado como umbral de elegibilidad para ICI en cáncer esofágico metastásico. Esófago...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-PDL1-CPS-ESOPHAGEAL |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-07 | actionability review required |
| Enfermedades | DIS-ESOPHAGEAL |
| Fuentes | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-PDL1-CPS |
|---|---|
| Enfermedad | DIS-ESOPHAGEAL |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | pembrolizumab + cisplatin + fluoropyrimidine (CPS≥10 SCC 1L per SRC-NCCN-ESOPHAGEAL-2025), pembrolizumab monotherapy (CPS≥10 SCC/adeno 2L per SRC-NCCN-ESOPHAGEAL-2025) |
| Resumen de las pruebas | PD-L1 CPS used as eligibility threshold for ICI in metastatic esophageal cancer. Esophageal SCC: CPS ≥10 — pembrolizumab + cisplatin + fluoropyrimidine 1L (KEYNOTE-590), and pembrolizumab monotherapy 2L (KEYNOTE-181 CPS≥10 subgroup). Esophageal adeno and GEJ: same CPS criteria as gastric adeno (NCCN 2025 treats GEJ adeno with gastric algorithm). Testing by IHC 22C3 pharmDx mandatory. Threshold-gated indication selection is performed by the algorithm layer (IND-ESOPH-METASTATIC-2L-PEMBRO-CPS10); this BMA entry surfaces ESCAT tier context only. |
Notas
Variant_qualifier null — threshold gating (CPS≥10) enforced by indication layer. KEYNOTE-590 and KEYNOTE-181 source stubs not yet ingested; citing NCCN/ESMO as proxies until trial source backfill PRs add them.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.